Impact of activating androgen receptor (AR) mutations on AR sensitivity to alternative ligands and response to ODM-208, a selective, first-in-class CYP11A1 inhibitor, in patients with advanced metastatic castration-resistant prostate cancer (mCRPC)
Bernard-Tessier, A. Utriainen, T. Barthelemy, P. Lallous, N. Gleave, M. Ikonen, T. Riikonen, R. Pohjanjousi, P. Garratt, C.
Bernard-Tessier, A.
Utriainen, T.
Barthelemy, P.
Lallous, N.
Gleave, M.
Ikonen, T.
Riikonen, R.
Pohjanjousi, P.
Garratt, C.
Citations
Altmetric:
Abstract
Affiliation
Description
Date
2022
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Bernard-Tessier A, Utriainen T, Cook N, Barthelemy P, Lallous N, Gleave M, et al. Impact of activating androgen receptor (AR) mutations on AR sensitivity to alternative ligands and response to ODM-208, a selective, first-in-class CYP11A1 inhibitor, in patients with advanced metastatic castration-resistant prostate cancer (mCRPC). Journal of Clinical Oncology. 2022 Jun;40(16). PubMed PMID: WOS:000863680301476.